We propose to supplement the Alzheimer's Disease Neuroimaging Initiative (ADNI) study by imaging amyloid plaque burden with positron emission tomography (PET) and Pittsburgh Compound B (PIB) in a subset of ADNI subjects who are scheduled to receive [F-i8]2-fluoro-2-deoxyglucose (FDG) PET scans as part of the funded five year ADNI imaging protocol. Neuropathologically, Alzheimer's disease (AD) is defined by the presence of plaques composed of the amyloid-beta (Ap) protein. This alone makes identification of AD pathology in living subjects an important goal because it could allow refinement of early diagnosis and identification of pre-symptomatic pathology for use as a biomarker. In addition, the optimal development of new anti-amyloid therapies will require a means to monitor brain amyloid load. PIB PET scans will be conducted in 24 control, 48 mild cognitive impairment (MCI), and 24 AD subjects at 16 ADNI PET sites immediately prior to FDG PET scans in subjects enrolled in the ADNI FDG PET imaging protocol. Controls and MCI subjects will be scanned at entry (baseline), 12, 24, and 36 months. AD subjects will be scanned at baseline, 12 and 24 months. These supplementary PIB PET studies will make full use of ADNI resources including administrative support of the ADNI Coordinating Center at UC San Diego as well as of existing MR and PET scanner quality control programs and data storage, management, and retrieval programs. Investigators at the University of Pittsburgh will analyze the PIB PET data using established image-based methods and post the results on the ADNI Laboratory of Neuroimaging (LONI) server for dissemination. The proposed supplemental PIB PET studies will provide unique, yet complementary, functional imaging data of the prevalence and amount of AP plaque binding in these subjects and further extend the objectives, hypotheses, and specific aims of the original ADNI grant.
Specific Aims of the PIB PET Supplement include: i) determine differences in the quantity and regional distribution of PIB retention in control, MCI, and AD subjects and relate these differences to cognitive, glucose metabolic, and structural MR measures in the same subjects collected by ADNI investigators; 2) determine how the quantity and regional distribution of PIB retention changes over time in control, MCI, and AD subjects and relate these changes to cognitive, glucose metabolic, and structural MR change measures determined in the same subjects by ADNI investigators; and 3) correlate PIB retention in whole brain and individual regionsof-interest to blood, urine and CSF biomarkers. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AG024904-03S3
Application #
7145299
Study Section
National Institute on Aging Initial Review Group (NIA)
Program Officer
Buckholtz, Neil
Project Start
2004-09-30
Project End
2009-08-31
Budget Start
2007-05-01
Budget End
2007-08-31
Support Year
3
Fiscal Year
2007
Total Cost
$985,840
Indirect Cost
Name
Northern California Institute Research & Education
Department
Type
DUNS #
613338789
City
San Francisco
State
CA
Country
United States
Zip Code
94121
Lee, Catherine; Betensky, Rebecca A; Alzheimer's Disease Neuroimaging Initiative (2018) Time-to-event data with time-varying biomarkers measured only at study entry, with applications to Alzheimer's disease. Stat Med 37:914-932
Varma, Vijay R; Oommen, Anup M; Varma, Sudhir et al. (2018) Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS Med 15:e1002482
Ngwa, Julius S; Fungwe, Thomas V; Ntekim, Oyonumo et al. (2018) Associations of Pulse and Blood Pressure with Hippocampal Volume by APOE and Cognitive Phenotype: The Alzheimer's Disease Neuroimaging Initiative (ADNI). Dement Geriatr Cogn Disord 45:66-78
Roostaei, Tina; Felsky, Daniel; Nazeri, Arash et al. (2018) Genetic influence of plasma homocysteine on Alzheimer's disease. Neurobiol Aging 62:243.e7-243.e14
Belathur Suresh, Mahanand; Fischl, Bruce; Salat, David H et al. (2018) Factors influencing accuracy of cortical thickness in the diagnosis of Alzheimer's disease. Hum Brain Mapp 39:1500-1515
Sexton, Corinne E; Ebbert, Mark T W; Miller, Ryan H et al. (2018) Common DNA Variants Accurately Rank an Individual of Extreme Height. Int J Genomics 2018:5121540
Cruchaga, Carlos; Del-Aguila, Jorge L; Saef, Benjamin et al. (2018) Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. Alzheimers Dement 14:205-214
Klinger, Rebecca Y; James, Olga G; Borges-Neto, Salvador et al. (2018) 18F-florbetapir Positron Emission Tomography-determined Cerebral ?-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery. Anesthesiology 128:728-744
Malpetti, Maura; Sala, Arianna; Vanoli, Emilia Giovanna et al. (2018) Unfavourable gender effect of high body mass index on brain metabolism and connectivity. Sci Rep 8:12584
Acosta, Diana; Powell, Fontasha; Zhao, Yize et al. (2018) Regional vulnerability in Alzheimer's disease: The role of cell-autonomous and transneuronal processes. Alzheimers Dement 14:797-810

Showing the most recent 10 out of 1666 publications